Skip to main content

One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on May 27, 2025.

via HealthDay

TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive breast cancer who have undergone breast surgery, according to a study presented at the European Society for Radiotherapy and Oncology, held from May 2 to 6 in Vienna.

Adrian M. Brunt, M.B.B.S., from Keele University in Stoke-on-Trent, England, and colleagues randomly assigned 4,110 patients with invasive breast cancer (pT1-3 pN0-1 M0) who had undergone breast surgery to 40 gray in 15 fractions (40Gy/15Fr) over three weeks, 27Gy/5Fr over one week, or 26Gy/5Fr over one week of radiotherapy to the whole breast/chest wall. The primary end point was five-year ipsilateral breast tumor recurrence; follow-up continued to 10 years.

The researchers identified 116 ipsilateral breast tumor recurrences over 10-year follow-up. The shorter radiotherapy schedule provides a similar level of cancer control to standard treatment, with no additional long-term side effects observed. Breast tumor recurrence occurred in 3.6 percent of patients in the 40Gy/15Fr group and in 2.0 percent of patients in the 26Gy/5Fr group, meeting the criteria for noninferiority.

"This 10-year analysis provides definitive long-term evidence that one-week radiotherapy to the breast is a safe, effective, and more practical option for breast cancer patients," Brunt said in a statement.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma

FRIDAY, July 18, 2025 -- Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV...

Velar Adhesion Reduces Cleft Width Prior to Palatoplasty in Cleft Lip

TUESDAY, July 15, 2025 -- For patients with unilateral cleft lip and palate (UCLP), velar adhesion (VA) reduces cleft width prior to palatoplasty and is associated with a lower...

AI Support Improves Breast Cancer Detection Accuracy in Mammography

MONDAY, July 14, 2025 -- Artificial intelligence (AI) support improves radiologists' breast cancer detection accuracy when reading mammograms, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.